/CNW/ - Theratechnologies Inc. ("Theratechnologies" or the "Company") (Nasdaq: THTX) (TSX: TH), a biopharmaceutical company focused on the development and...
/PRNewswire/ - Paul Lévesque, President and Chief Executive Officer, Hamilton Thorne Ltd. ("Theratechnologies", the "Company", or "we") (TSX: TH) shares his...
/CNW/ - Paul Lévesque, President and Chief Executive Officer, Hamilton Thorne Ltd. ("Theratechnologies", the "Company", or "we") (TSX: TH) shares his Company's...
/CNW/ - This press release is being disseminated as required by National Instrument 62–103 - The Early Warning System and Related Take Over Bids and Insider...
Montreal, Quebec--(Newsfile Corp. - April 18, 2023) - Theratechnologies (NASDAQ: THTX) (TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies,...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. ("Theratechnologies" or the "Company") (NASDAQ: THTX)....
MONTREAL, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical...
New sub-analysis on Trogarzo clinical trial patients demonstrates that long-term viral suppression is not influenced by partially active agents. Predictive...
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form...
– Q2 2022 Consolidated Sales Growth of 8.3% to $19.3 million – Year-to-Date Revenue Growth of 13.9% or $37.8 million – Year-to-Date EGRIFTA SV® Revenue...